Targeting PRAME in PD-1–Refractory Melanoma

Dr Luke discusses the rationale for evaluating IMA203 in cutaneous melanoma and what the PRAME trial findings may mean for the future of TCR therapy.

The phase 3 SUPRAME trial is comparing IMA203 vs investigator’s choice of therapy in patients with pretreated unresectable or metastatic cutaneous melanoma.

Justin Moser, MD, discusses the ongoing phase 3 SUPRAME trial investigating IMA203 in previously treated, unresectable or metastatic cutaneous melanoma.

Justin Moser, MD, discusses the design and implications of the SUPRAME trial investigating IMA203 in pretreated advanced cutaneous melanoma.

Jason J. Luke, MD, FACP, discusses data for the PRAME-targeted TCR T-cell therapy IMA203 in advanced or metastatic melanoma.

Jason Luke, MD, discusses IMA203 vs investigator’s choice of standard therapy in patients with previously treated advanced cutaneous melanoma.

IMA203 was well tolerated and elicited durable responses in patients with advanced melanoma.